Condition: Astrocytoma, IDH-Mutant, Grade 3 · Sponsor: Alliance for Clinical Trials in Oncology
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Vorasidenib citrate blocks the proteins made by the mutated IDH1 and IDH2 genes, which may help keep tumor cells from growing. It is a type of enzyme inhibitor and a type of targeted therapy. Adding vorasidenib to the usual treatment, temozolomide, may be more effective than temozolomide alone in treating patients with newly diagnosed grade 3 astrocytoma after radiation therapy.
This description comes directly from the study's public registry record.
Alexandra Alexandra LeVasseur · 773-834-4518 · alevasseur@bsd.uchicago.edu
Always discuss trial participation with your own doctor first.
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Recruiting |
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine, California, United States | Recruiting |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange, California, United States | Recruiting |
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care Center-Trumbull | Trumbull, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care Center - Waterford | Waterford, Connecticut, United States | Recruiting |
| Helen F Graham Cancer Center | Newark, Delaware, United States | Recruiting |
| Medical Oncology Hematology Consultants PA | Newark, Delaware, United States | Recruiting |
| OSF Saint Joseph Medical Center | Bloomington, Illinois, United States | Recruiting |
| Illinois CancerCare-Bloomington | Bloomington, Illinois, United States | Recruiting |
| Illinois CancerCare-Canton | Canton, Illinois, United States | Recruiting |
+ 70 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07215910